Project Grant R01DA064355
Award Date
8/1/25
Completion Date
4/30/30
Dollars Obligated
$660K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded a $154,568 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Washington University in St. Louis. The grant, titled "Investigating the Role of Dorsal Raphe Nucleus Enkephalin Neurons in Motivational and Affective Behaviors During Chronic Pain", aims to determine the contribution of endogenous opioids in the dorsal raphe nucleus to motivational and affective dysregulation during chronic pain. The...
The National Institute on Drug Abuse (NIDA) awarded a $137,619 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Washington. The grant, awarded on January 19, 2025, will support research to investigate the role of tetrahydrocannabinol (THC) in mediating pain signaling in the basolateral amygdala (BLA) brain region. The study aims to determine how THC, acting through cannabinoid 1 receptors (CB1R), alters glutamatergic neuronal activity in the BLA...
This $675,107 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders supports research by Northeastern University to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The key objectives are to: 1) design and synthesize new cannabinoid CB1 receptor allosteric agonist-positive allosteric modulator (CB1R AGO-PAM) and CB2 receptor...
This federal Project Grant award of $153,000.00 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports a 6-month longitudinal study to examine the relationship between cannabis use, pain perception, and daily functioning in young adults with chronic pain. The research will use an ecological momentary assessment (EMA) design to capture real-time data on cannabis use, pain, physical activity, and sleep over...
The National Institute on Drug Abuse (NIDA) awarded a $515,088 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Washington University in St. Louis. The grant, titled "Promoting Excellence through Pain and Addiction Research Enhancement (PREPARE)", aims to recruit and train 5 postdoctoral fellows (4 T90, 1 R90) to conduct mechanistically-based clinical research on the intersection of chronic pain and substance use disorders (SUD). The program will...
This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $233,250 to The Washington University in St. Louis to examine the relationship between early cannabis use and later opioid use disorder. The key objectives are to: 1) Estimate the association between early cannabis use and both proximal and distal aspects of opioid involvement, including whether the relationships are modified by co-occurring...
This Federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $146,922 to The Johns Hopkins University to evaluate the role of endocannabinoid receptors, including CB1, CB2, TRPV2, and PPAR-α, in modulating the inflammatory response of microglia to HIV infection. The goal is to develop a better understanding of how cannabinoids, such as cannabidiol (CBD), can potentially mitigate the chronic...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $118,457 to The Trustees of the University of Pennsylvania to conduct research aimed at harnessing the genetics of chronic pain to inform the development of non-addictive analgesic medications. The 4-year project, starting on April 15, 2025, will characterize the genetic architecture underlying chronic pain liability and addiction, estimate...
This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...